Silence Therapeutics PLC ADR SLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
-
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
-
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
-
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $9.29
- Day Range
- $8.91–9.85
- 52-Week Range
- $4.19–11.06
- Bid/Ask
- $9.30 / $12.00
- Shares Outstanding
- 47.23M
- Market Cap
- $460.54M
- Volume/Avg
- 266 / 392,239
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 548.89
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 88
Valuation
|
Metric
|
SLN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.32 |
Price/Sales | 548.89 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SLN
|
|---|---|
Quick Ratio | 8.82 |
Current Ratio | 9.83 |
Interest Coverage | — |
Quick Ratio
SLN
Profitability
|
Metric
|
SLN
|
|---|---|
Return on Assets (Normalized) | −42.23% |
Return on Equity (Normalized) | −187.90% |
Return on Invested Capital (Normalized) | −187.30% |
Return on Assets
SLN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|LxM$@r^ | LOCK|@n<?M | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|R>Bt>$w | LOCK|rth&s | $69B | |||
| argenx SE ADR
ARGX
| LOCK|WglRK$n | LOCK|#gD | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%@$#hs | LOCK|j?#c> | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?rL$!Xb | LOCK|dk% | $36B | |||
| Moderna Inc
MRNA
| LOCK|d<>V?>W | LOCK|Xkm | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<mM%VrVZ | LOCK|&&@^r | $25B | |||
| Incyte Corp
INCY
| LOCK|zx$dctM | LOCK|<D | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Y$^HWZ% | LOCK|@< | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!#W!^$> | LOCK|Wb! | $16B |
United States